Meletta Romana, Slavik Roger, Mu Linjing, Rancic Zoran, Borel Nicole, Schibli Roger, Ametamey Simon M, Krämer Stefanie D, Müller Herde Adrienne
Department of Chemistry and Applied Biosciences of ETH Zurich, Center for Radiopharmaceutical Sciences of ETH, PSI and USZ, Vladimir-Prelog-Weg 1-5/10, 8093 Zurich, Switzerland.
Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland.
Nucl Med Biol. 2017 Apr;47:31-43. doi: 10.1016/j.nucmedbio.2017.01.001. Epub 2017 Jan 8.
Endarterectomized human atherosclerotic plaques are a valuable basis for gene expression studies to disclose novel imaging biomarkers and therapeutic targets, such as the cannabinoid receptor type 2 (CB2). In this work, CB2 is expressed on activated immune cells, which are abundant in inflamed plaques. We evaluated the CB2-specific radiotracer [C]RS-016 for imaging vascular inflammation in human and mouse atherosclerotic lesions.
The differential gene expression of microscopically classified human carotid plaques was evaluated using quantitative polymerase chain reaction. In addition, CB2 expression levels in human plaques were investigated by in vitro autoradiography. As an appropriate animal model we used apolipoprotein E knockout mice (ApoE KO) with shear stress-induced atherosclerosis to evaluate CB2 levels in vivo. Positron emission tomography (PET) was performed with both the CB2 radioligand [C]RS-016 and the metabolic radiotracer [F]fluorodeoxyglucose ([F]FDG) at various time points. Retrospectively, carotids were dissected for histopathology and gene expression analysis.
We identified 28 human genes differentially expressed in atherosclerotic plaques compared to normal arteries of which 12 were upregulated preferentially in vulnerable plaques. The latter group included members of matrix metalloproteinase family and the T-lymphocyte activation antigens CD80 and CD86. CB2 was upregulated by 2-fold in human atherosclerotic plaques correlating with CD68 expression levels. Specific in vitro binding of [C]RS-016 was predominantly observed to plaques. In vivo PET imaging of ApoE KO mice revealed accumulation of [C]RS-016 and [F]FDG in atherosclerotic plaques. Development of advanced plaques with elevated CB2 and CD68 levels were found in vitro in ApoE KO mice resembling human vulnerable plaques.
We identified human genes associated with plaque vulnerability, which potentially could serve as novel imaging or therapeutic targets. The CB2-specific radiotracer [C]RS-016 detected human plaques by in vitro autoradiography and accumulated in vivo in plaques of ApoE KO mice, however not exclusively in vulnerable plaques.
经动脉内膜切除术获取的人类动脉粥样硬化斑块是基因表达研究的宝贵基础,有助于揭示新型成像生物标志物和治疗靶点,如2型大麻素受体(CB2)。在这项研究中,CB2在活化免疫细胞上表达,这些细胞在炎症斑块中大量存在。我们评估了CB2特异性放射性示踪剂[C]RS-016用于成像人类和小鼠动脉粥样硬化病变中的血管炎症。
使用定量聚合酶链反应评估显微镜分类的人类颈动脉斑块的差异基因表达。此外,通过体外放射自显影研究人类斑块中CB2的表达水平。作为合适的动物模型,我们使用载脂蛋白E基因敲除小鼠(ApoE KO),通过剪切应力诱导动脉粥样硬化,以评估体内CB2水平。在不同时间点,使用CB2放射性配体[C]RS-016和代谢放射性示踪剂[F]氟脱氧葡萄糖([F]FDG)进行正电子发射断层扫描(PET)。回顾性地,解剖颈动脉进行组织病理学和基因表达分析。
我们鉴定出与正常动脉相比,动脉粥样硬化斑块中28个人类基因差异表达,其中12个在易损斑块中优先上调。后一组包括基质金属蛋白酶家族成员以及T淋巴细胞活化抗原CD80和CD86。人类动脉粥样硬化斑块中CB2上调2倍,与CD68表达水平相关。[C]RS-016的特异性体外结合主要在斑块中观察到。ApoE KO小鼠的体内PET成像显示[C]RS-016和[F]FDG在动脉粥样硬化斑块中积聚。在体外,在ApoE KO小鼠中发现了类似于人类易损斑块的、CB2和CD68水平升高的晚期斑块。
我们鉴定出与斑块易损性相关的人类基因,这些基因可能作为新型成像或治疗靶点。CB2特异性放射性示踪剂[C]RS-016通过体外放射自显影检测到人类斑块,并在体内积聚在ApoE KO小鼠的斑块中,但并非仅在易损斑块中。